Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28959862 | 0.73 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL4968787 | 0.72 | ALDH1A1 (0.40) | ALDH1A1 | |
| SCHEMBL4738792 | 0.69 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL2864827 | 0.69 | ALDH1A1 (0.42) | ALDH1A1 | |
| SCHEMBL11272259 | 0.68 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL7156104 | 0.68 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL9733652 | 0.67 | — | — | |
| SCHEMBL1091612 | 0.65 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL27439203 | 0.60 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL24230090 | 0.59 | PDE4A (0.40) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2038249-B1 | PROCESS FOR PREPARING GABAPENTIN | ZACH SYSTEM SPA (IT) | 2013-09-11 | — | — | EP | disclosed |
| US-8143443-B2 | Process for preparing gabapentin | ZACH SYSTEM S.P.A. (IT) | 2012-03-27 | — | — | US | disclosed |
| US-20100029983-A1 | PROCESS FOR PREPARING GABAPENTIN | ZACH SYSTEM S.P.A. (IT) | 2010-02-04 | — | — | US | disclosed |
| US-5175306-A | Intermediates for hypotensive agents | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-12-29 | — | — | US | disclosed |
| US-4822894-A | PURE CIS ENANTIOMERS OF FUSED PYRROLE RING CARBOXYLATES | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-04-18 | — | — | US | disclosed |
| EP-0094633-B1 | SPIRO-2-AZA-ALKANE-3-CARBONITRILES, PROCESS FOR THEIR PREPARATION AND THEIR USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-11-09 | — | — | EP | disclosed |
| EP-0115345-B1 | PROCESS FOR THE RESOLUTION OF RACEMIC OPTICALLY ACTIVE BICYCLIC IMINO-ALPHA-CARBOXYLIC ACID ESTERS AND USE OF THE COMPOUNDS OBTAINABLE IN THIS WAY FOR THE SYNTHESIS OF CARBOXYALKYL DIPEPTIDES | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-01-07 | — | — | EP | disclosed |
| US-4668796-A | Racemates of optically active bicyclic imino-alpha-carboxylic esters | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-05-26 | — | — | US | disclosed |
| US-4515960-A | INTERMEDIATES FOR HYPOTENSIVES | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-05-07 | — | — | US | disclosed |
| EP-0115345-A1 | Process for the resolution of racemic optically active bicyclic imino-alpha-carboxylic acid esters and use of the compounds obtainable in this way for the synthesis of carboxyalkyl dipeptides | HOECHST AKTIENGESELLSCHAFT (DE) | 1984-08-08 | — | — | EP | disclosed |
| EP-0094633-A2 | Spiro-2-aza-alkane-3-carbonitriles, process for their preparation and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029983-A1 | PROCESS FOR PREPARING GABAPENTIN | GABRB1, GABRG1, OGDH | ALDH1A1 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.